5752 RESULTS
Sort By:
Parkinson's disease is one of the most common neurodegenerative diseases, affecting about one percent of all people over the age of 65. It is characterized by rigidity, bradykinesia and tremors, which are caused by the progressive degeneration of dopamine-containing neurons...
Topline results suggested that the anti-inflammatory treatment stabilized cognition and function over six months. The trial did not include biomarkers.
Progressive supranuclear palsy is a poorly understood movement disorder that has come to be of intense interest to age-related neurodegenerative disease researchers...
Assays will help doctors diagnose Alzheimer’s disease and amnestic mild cognitive impairment in Taiwanese clinics.
Besides the big-gun antibodies and BACE inhibitors, smaller, lesser-known drug programs are inching their way through the clinical trials pipeline. As is often the case, Phase 1 seems encouraging.
Despite plaques and tangles in the brain, this group, on average, maintains their cognitive skills over two to four years, suggesting the presence of resilience factors.
Among 14 familial Alzheimer’s APP mutations, two don’t change the Aβ42/Aβ40 ratio, but all of them yield long peptides of 45 to 49 residues that hide out in the membrane.
New genetic variants emerged by harmonizing whole-exome-sequencing data across continents, and by using imputation to plumb the depths of existing GWAS. One variant encodes a microglial phospholipid transporter.
Online training for use of Amyvid, the first FDA-approved Aβ imaging ligand, is now up and running,even as a task force convened by the Society of Nuclear Medicine and the Alzheimer's Association scrambles to formulate some expert guidelines on how ...
The rarest kind of Alzheimer's disease, the form that is inherited from parent to child with a cruel 50 percent likelihood, has long been marked by its untapped opportunities. Affected families have made possible both the discovery of the first three ...
A $40 million multicenter biomarker study for Parkinson disease progression is off and running, with enrollment underway at 10 of 18 sites in the U.S. and Europe. In design and operation, the Parkinson's Progression Markers Initiative (PPMI) ...
Researchers split $200,000 for their theories on the role of six microbes—one virus, four bacteria, and one parasite—in Alzheimer’s.
Last year's ice bucket challenge for amyotrophic lateral sclerosis netted $220 million in donations for ALS charities, and the 2015 challenge is off to a strong start with $100,000 from Major League Baseball. Alzforum looks at how all that money is ...
The Alzheimer's Disease Neuroimaging Initiative is the most expensive AD study the NIH has ever funded. Expectations are that it will speak with the authoritative voice of a 58-center, three-year observation of 819 research participants above a ...
The commercial test uses a few drops of saliva. It must be ordered by a physician. Plans are also in the works to use the test to select participants for clinical trials.
